Answers are grounded in this paper and cite their sources.
Abstract The aim of this prospective, international multicenter, pseudorandomized study using the donor versus no-donor concept to compare RICT HCT to standard-of-care chemotherapy in intermediate- or high risk AML patients 50 – 70 years in CR1. Part 1 included only patients with potential family donors (RD) at the date of HLA-typing of the first potential sibling or CR-date, if later. In Part 2), patients without a possible sibling donor could be included with the inclusion date at the start of an unrelated donor (URD) search. 360 patients were registered and 309 analyzed. The median follow-up was 47 months (1-168). There was no difference in overall survival (OS) between the RD (n=124) and the Control (n=77) groups (p=0.50, 3-year OS RD: 0.41(95% CI; 0.32-0.50); Controls: 0.49 (95% CI; 0.37-0.59)). The main cause of death was relapse (67% RD; 88% Controls). Comparing URD-HCT (n=86) and Controls (n=20), the 3-year survival was 0.60 (95% CI 0.50-0.70) for URD-HCT and 0.37 (95% CI 0.13-0.62) in the Controls, respectively (p=.10). When analyzing transplanted patients (Part 2), the OS at 3-years was higher for URD-HCT than RD-HCT (0.67 (0.55-0.76) vs. 0.42 (0.26-0.57; p=.005). The risks for severe acute and extensive chronic GVHD were lower in the URD-HCT group.
No takes yet. Share an insight, caveat, or question.
Ljungman et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: